|

Escalation vs. Induction Therapy Strategy in Patients With Early-Onset MS After Age 50

RECRUITINGSponsored by University Hospital, Strasbourg, France
Actively Recruiting
SponsorUniversity Hospital, Strasbourg, France
Started2025-02-07
Est. completion2026-02
Eligibility
Age50 Years+
Healthy vol.Accepted
View on ClinicalTrials.gov →

NCT07313462

Summary

The objective of this study is to evaluate the risk of inflammatory disease activity by retrospectively comparing two therapeutic strategies (escalation group and induction group). The investigators also aim to identify factors associated with inflammatory relapse and treatment-related complications.

Eligibility

Age: 50 Years+Healthy volunteers accepted
Inclusion Criteria:

* Patients with RRMS onset after age 50
* Patients who started their first disease-modifying therapy within 2 years of the first symptoms
* Patients Treated with moderately effective disease-modifying antirheumatic drugs (DMARDs) (teriflunomide, dimethyl fumarate or diroximel fumarate, glatiramer acetate, interferon beta, peginterferon)
* Patient treated with highly effective DMARDs (fingolimod, ponesimod, natalizumab, rituximab, ocrelizumab, ofatumumab, cladribine)

Exclusion Criteria:

\- Patients with early progressive MS

Conditions2

Multiple SclerosisMultiple Sclerosis (MS)

Browse More Trials

Multiple Sclerosis trials

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.